Catalyst Dossier · compiled by CeliA 🧫

MYLAN (VTRS)

Pharmaceutical Preparations · market cap $17.9B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Viatris Inc. (VTRS) is a global generics and branded pharmaceutical company formed via the 2020 merger of Mylan and Upjohn (a Pfizer legacy division), headquartered in Canonsburg, PA with ~32,000 employees and a $18.3B market cap. The company carries a heavy $12.5B net debt load against declining revenues ($14.3B in 2025 vs. $17.9B in 2021) and posted a $3.5B net loss in 2025, while managing a broad late-stage pipeline spanning generics, biosimilars, and branded assets. Near-term catalysts center on a transdermal progestin contraceptive system with two Phase 3 readouts expected in 2027.

The catalyst path

2026-08-06Earningsimp 5/10
2026-10-17NDA Filingimp 7/10
2026-11-30 (est.)Phase 2 · MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)imp 7/10
2026-12-31Phase 3imp 8/10
2027-03-15 (est.)Phase 3 · Transdermal system containing progestinimp 9/10
2027-05-15 (est.)Phase 3 · Transdermal system containing progestinimp 9/10

Pipeline

Asset	Phase	Indication
ziprasidone versus olanzapine , risperidone or quetiapine	Phase 3	Schizophrenia
Amlodipine/atorvastatin single pill	Phase 3	Hypertension
MYL-1601D Product	Phase 3	Diabetes Mellitus, Type 1
venlafaxine ER 75 mg/day (fixed dose)	Phase 3	Major Depressive Disorder
Risperidone	Phase 3	Schizophrenia
LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION	Phase 3	Glaucoma, Primary Open Angle (POAG)
Revefenacin	Phase 3	Chronic Obstructive Pulmonary Disease, COPD
sertraline/[S,S]-reboxetine	Phase 2	Depressive Disorder, Major
Econazole Nitrate Cream, 1%	Phase 3	Tinea Pedis
Eletriptan 20 mg	Phase 3	Migraine With or Without Aura
Eletriptan 80 mg	Phase 3	Migraine With or Without Aura
TD-4208 700 μg	Phase 2	Chronic Obstructive Pulmonary Disease, COPD
MR-107A-01	Phase 2	Pain
pramipexole	Phase 3	Restless Legs Syndrome
Diclofenac sodium gel 1%	Phase 3	Osteoarthritis, Knee
tolterodine extended release capsule	Phase 3	Urinary Incontinence
iv sildenafil	Phase 3	Pulmonary Hypertension, Familial Persistent, of the Newborn
MR-130A-01 Transdermal patch	Phase 2	Contraception
MR-107A-02	Phase 2	Acute Pain
olanzapine	Phase 3	Schizophrenia

Price & technical context

3-month

+22.5%

6-month

+33.2%

12-month

+78.8%

52-wk range

$8.74–$17.39

vs 50-day MA

+4.4%

vs 200-day MA

+26.3%

Realized vol

32.1%

Max drawdown

-45.7%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VTRS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.